Demystifying Global Kidney Trials: Two New Case Studies in the ‘Guide for Everyone’
The “ISN Global Kidney Trials Insights: A Guide for Everyone” has expanded to include two new case studies. Based on the ISN-ACT Global Trials Focus (GTF) summaries, the guide translates complex trial findings into accessible information to help those living with kidney diseases and others better understand advancements in kidney care.
Access the simplified summaries here
The latest additions examine whether a new drug can reduce protein levels in the urine of people with chronic kidney disease (CKD) and whether semaglutide (Ozempic) could slow kidney disease progression in patients with both type 2 diabetes and CKD.
Duane Sunwold, ISN-ACT Global Trials Focus subgroup member, commented: “As a patient involved in the ISN Global Kidney Trials Insights project, I had the incredible opportunity to contribute to a truly valuable resource for the kidney disease community. This collaborative effort, which brings together medical experts and patients, has the potential to significantly improve the understanding of complex clinical trials for individuals who may not have a strong medical background.
Working alongside a knowledgeable physician to create patient-friendly overviews was incredibly fulfilling, and I gained a deeper understanding of the research being conducted. I often wished for such clear and accessible information when I was first diagnosed, and I’m proud to be part of a project that can make a real difference for others.”
Explore the Global Kidney Patient Organizations map here.
Read the Global Trials Focus summaries here.